Biopharmaceuticals

#Biopharmaceuticals #Informatics

Weighing in Compliance with European Pharmacopoeia Chapter 2.1.7

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.   Balances for Analytical Purposes aims to ensure quality control of… Read More

#Intelligence #Resources

#Biopharmaceuticals #Informatics

Cubis Laboratory Balances in Vaccine Research and Development

Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save millions of lives. Along the continuous emergence of new diseases and… Read More

#Intelligence #Resources

#Biopharmaceuticals #Drug development #Webinar

Webinar: learn how to accelerate biosimilar development

Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which will be hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. Join Dr Richard L Easton, Technical Director of Structural Analysis at BioPharmSpec as he discusses… Read More

#News #Trending News

#Biopharmaceuticals #Biotechnology #Drug innovation

Sciex launches capillary electrophoresis solution

Sciex has launched a capillary electrophoresis solution, the BioPhase 8800 system. The multi-capillary system for CE-SDS processes eight samples simultaneously, retaining sample integrity and delivering consistent results.  The development of biopharmaceutical therapies requires the ability to measure and monitor critical quality attributes in short timelines. The BioPhase 8800… Read More

#News

#Biopharmaceuticals #Clinical trials #Drug development #Drug discovery

Building a pipeline of clinically-differentiated cancer therapies 

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.   MT: You previously commented that this study marks the… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biopharmaceuticals #Clinical trials #Data #Global data

New results in psoriasis pave way for potential best in class

UCB, a biopharmaceutical company, has presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for… Read More

#News

#AI / data analytics / healthtech / informatics #Automation / robotics #Biopharmaceuticals #Covid-19 #CRISPR #Drug discovery #Immunology / Virology & Vaccines #Lab automation #Moderna #Molecular Biology #Pfizer #Sequencing

What has 2020 taught us about lab automation?

Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines… Read More

#Covid-19 #Exclusive Content #News

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#Awards #Biopharmaceuticals #Biotechnology #Clinical trials

Frost & Sullivan announces DCT award winner 

Thread, a technology and service provider for decentralised clinical trials, has been awarded a Frost & Sullivan award. The company scooped the Frost & Sullivan’s 2021 Customer Value Leadership Award in the decentralised clinical trials industry. “Thread’s innovations via its decentralised trials platform are sure… Read More

#News

#Animal testing #Biopharmaceuticals #R&D #Research

ABPI responds to new UK animal R&D statistics

The UK government has released a national statistics report, “Annual Statistics of Scientific Procedures on Living Animals, Great Britain, 2020”. In summary, 2.88 million procedures were carried out in Great Britain involving living animals in 2020. Key results of the report include the fact that the 2.88 million procedures in… Read More

#News #Trending News

#Biopharmaceuticals #Biotechnology #Drug development #Investment #Pharmaceuticals #Therapeutics

New laboratory boosts high-potency drug development

US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs. The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines. “Our… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug delivery #Drug development #Pharma #Pharmaceuticals

Half of pharma believes AI can help bring new drugs to market faster

New research reveals that 50% of European and US pharmaceutical manufacturing companies know artificial intelligence (AI) can help bring new drugs to market more rapidly and securely, but 96% face challenges with using it to derive value from their data. 49% of all executives surveyed say their company has no… Read More

#News

#Biopharmaceuticals #Biotechnology #Covid-19 #Health #Life sciences

UK pharma sees R&D spend hold up despite Brexit and Covid-19

A survey of 75 pharmaceutical, life sciences and medtech businesses indicates R&D spending is being maintained and is set to rise in 2021, despite Brexit and the impact of Covid-19. The survey included SMEs in these sectors in the UK and was conducted by accountancy group MHA. This is positive… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#Biopharmaceuticals #Drug discovery #Drug targets

Handbook for the modern antibody development process

The process of antibody discovery and development into a clinical candidate is one full of twists, turns and offshoots, yet one that an increasing number of researchers and companies, both small and large, have successfully navigated. This eBook released by Twist Biopharma is designed to be used as a… Read More

#News

#Biopharmaceuticals #Informatics

Antibody Discovery: From Target to Molecule

You’re about to embark on a journey of discovery. And like all journeys that are worthwhile, it’s far from linear. The process of antibody discovery and development into a clinical candidate is one full of twists, turns, roundabouts, and offshoots, yet one that an increasing number of researchers and companies,… Read More

#DDW eBooks #Intelligence